Gene therapy · developed by BioMarin Pharmaceutical
BMN 349 is a gene therapy investigated in alpha-1 antitrypsin deficiency, a condition caused by defective SERPINA1 gene function. The approach is designed to deliver a gene that supports alpha-1 antitrypsin production in the body.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06738017 | Phase 1 | Alpha 1-Antitrypsin Deficiency | Active not recruiting | BMRN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Alpha 1-Antitrypsin Deficiency
See BMRN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BMRN catalysts and pipeline →